For: | Ni XF, Wu CP, Jiang JT. Serum VEGFR-3 and survival of advanced gastric cancer patients treated with FOLFOX. World J Gastroenterol 2010; 16(17): 2163-2169 [PMID: 20440858 DOI: 10.3748/wjg.v16.i17.2163] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v16/i17/2163.htm |
Number | Citing Articles |
1 |
Luigina Graziosi, Andrea Mencarelli, Chiara Santorelli, Barbara Renga, Sabrina Cipriani, Emanuel Cavazzoni, Giuseppe Palladino, Stefan Laufer, Michael Burnet, Annibale Donini, Stefano Fiorucci. Mechanistic role of p38 MAPK in gastric cancer dissemination in a rodent model peritoneal metastasis. European Journal of Pharmacology 2012; 674(2-3): 143 doi: 10.1016/j.ejphar.2011.11.015
|
2 |
Hugo Héctor Ortega, Almudena Veiga-Lopez, Shilpa Sreedharan, Melisa María del Luján Velázquez, Natalia Raquel Salvetti, Vasantha Padmanabhan. Developmental Programming: Does Prenatal Steroid Excess Disrupt the Ovarian VEGF System in Sheep?1. Biology of Reproduction 2015; 93(3) doi: 10.1095/biolreprod.115.131607
|
3 |
Jia-Xiang An, Ming-Hui Ma, Chun-Dong Zhang, Shuai Shao, Nuo-Ming Zhou, Dong-Qiu Dai. miR-1236-3p inhibits invasion and metastasis in gastric cancer by targeting MTA2. Cancer Cell International 2018; 18(1) doi: 10.1186/s12935-018-0560-9
|
4 |
Huan Song, Jianwei Zhu, DongHao Lu. Molecular-targeted first-line therapy for advanced gastric cancer. Cochrane Database of Systematic Reviews 2016; 2016(7) doi: 10.1002/14651858.CD011461.pub2
|
5 |
Bo Hong, Jie Li, Chunxiao Huang, Tao Huang, Mengpei Zhang, Lijiang Huang. miR-300/FA2H affects gastric cancer cell proliferation and apoptosis. Open Medicine 2020; 15(1): 882 doi: 10.1515/med-2020-0188
|
6 |
Liangyu Bie, Ning Li, Wenying Deng, Xiaoyu Lu, Ping Guo, Suxia Luo. <p>Serum miR-191 and miR-425 as Diagnostic and Prognostic Markers of Advanced Gastric Cancer Can Predict the Sensitivity of FOLFOX Chemotherapy Regimen</p>. OncoTargets and Therapy 2020; : 1705 doi: 10.2147/OTT.S233086
|
7 |
Hilda Wong, Thomas Yau. Targeted Therapy in the Management of Advanced Gastric Cancer: Are We Making Progress in the Era of Personalized Medicine?. The Oncologist 2012; 17(3): 346 doi: 10.1634/theoncologist.2011-0311
|
8 |
D. Pietrowski, L. Szabo, M. Sator, A. Just, C. Egarter. Ovarian hyperstimulation syndrome is correlated with a reduction of soluble VEGF receptor protein level and a higher amount of VEGF-A. Human Reproduction 2012; 27(1): 196 doi: 10.1093/humrep/der349
|
9 |
Huan Song, Jianwei Zhu, DongHao Lu, Huan Song. Cochrane Database of Systematic Reviews. 2015; doi: 10.1002/14651858.CD011461
|
10 |
Thomas Thomaidis, Annett Maderer, Salah-Eddin Al-Batran, Janis Kany, Claudia Pauligk, Kristina Steinmetz, Arno Schad, Ralf Hofheinz, Harald Schmalenberg, Nils Homann, Peter Robert Galle, Markus Moehler. VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC Cancer 2014; 14(1) doi: 10.1186/1471-2407-14-476
|
11 |
Yang-kun Wang, Xue-xia Lv, Zhi-qiang Wang, Yong-mei Zhou, Bo Jiang, Su-nan Wang, Xiao-dong Chen. The significance of the microlymphangiogenesis, microangiogenesis, and combined detection of programmed cell death-1 protein (PD-1)/ki67 in gastric cancer tissues. Journal of Cancer Research and Clinical Oncology 2023; 149(11): 9129 doi: 10.1007/s00432-023-04709-y
|